• 629 Citations
  • 15 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

I am currently a Cancer Council SA Beat Cancer Early Career Research Fellow in the Myeloma Research Laboratory, Adelaide Medical School, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Precision Medicine Theme.

My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for approximately 80,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.

The progression and relapse of myeloma tumours is critically dependent on the ability of the myeloma tumour cells to disseminate to sites throughout the skeleton. In particular, previous studies have identified that those patients with highly disseminated disease at diagnosis do particularly poorly, leading to rapid disease progression and disease relapse. One of my primary research interests focuses on identifying the intrinsic and extrinsic factors involved in the recirculation and dissemination process in myeloma with the aim of developing therapeutic strategies that will prevent disease progression and overt relapse in these patients.

Education/Academic qualification

PhD, University of Adelaide

Bachelor of Science (Honours), University of New South Wales

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 629 Citations
  • 15 h-Index
  • 27 Article
  • 2 Review article
  • 1 Letter

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

Friend, N., Noll, J., Opperman, K. S., Clark, K. C., Mrozik, K., Vandyke, K., Hewett, D. & Zannettino, A., 1 Jan 2020, In : PLoS ONE. 15, 1, e0228408.

Research output: Contribution to journalArticle

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells

Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., Chai, R. C., De Veirman, K., Owen, K. L., Opperman, K. S., Vandyke, K., Clark, J. R., Seckinger, A., Kovacic, N., Nguyen, A., Mohanty, S. T., Pettitt, J. A., Xiao, Y., Corr, A. P., Seeliger, C. & 14 others, Novotny, M., Lasken, R. S., Nguyen, T. V., Oyajobi, B. O., Aftab, D., Swarbrick, A., Parker, B., Hewett, D., Hose, D., Vanderkerken, K., Zannettino, A., Amit, I., Phan, T. G. & Croucher, P. I., 4 Jul 2019, In : Blood. 134, 1, p. 30-43 14 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., Schwarz, N., Evdokiou, A., Croucher, P. I., Psaltis, P., Noll, J. E. & Zannettino, A., 1 Aug 2019, In : Neoplasia (United States). 21, 8, p. 777-787 11 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)